 |
|
|
| |
Changes in CVD Risk Factors with Immediate and
Deferred ART in the START Trial
|
| |
| |
Reported by Jules Levin
CROI 2016 Feb 22-24 Boston
Jason V. Baker1,2, Shweta Sharma3, Amit Achhra4, Jose Ignacio Bernardino5, Johannes R Bogner6, Daniel Duprez1, Sean Emery4, Brian Gazzard7, Jonathan Gordin8, Greg Grandits3, Andrew Phillips9, Siegfried Schwarze10, Elsayed Z. Soliman11, Stephen A. Spector12, Giuseppe Tambussi13, and Jens Lundgren14 for the INSIGHT START (Strategic Timing of AntiRetroviral Treatment) Study Group
1Department of Medicine, University of Minnesota, USA; 2Division of Infectious Diseases, Hennepin County Medical Center, USA; 3Division of Biostatistics, University of Minnesota, USA; 4Kirby Institute, University of New South Wales, Australia; 5Department of Medicine. Hospital La Paz. IdiPAZ, Spain; 6Division of Infectious Diseases, MedIV, University Hospital of Munich, Germany; 7Chelsea and Westminster Hospital, UK; 8Division of Cardiology, David Geffen School of Medicine at University of California, USA; 9HIV Epidemiology & Biostatistics Group, University College London, UK; 10European AIDS Treatment Group, Germany; 11Epidemiological Cardiology Research Center, Wake Forest School of Medicine, USA; 12Division of Pediatric Infectious Diseases, University of California San Diego and Rady Children’s Hospital, USA; 13San Raffaele Scientifi Institute, Italy;14CHIP, Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Denmark
|
| |
|
|
|
|
|
